Indian Pharmacopoeia Commission

IPC Collaborates with Bihar, Maharashtra & Mizoram to Advance Medicine Safety and Rational Use of Medicines

The Indian Pharmacopoeia Commission (IPC), under the Ministry of Health & Family Welfare, Government of India, signed Memoranda of Understanding (MoUs) with the State Pharmacy Councils of Bihar, Maharashtra, and Mizoram to strengthen collaborative efforts towards rational use of medicines, pharmacovigilance, and patient safety initiatives.

The collaboration will support:
✔ Promotion of National Formulary of India (NFI)
✔ ADR reporting & medicine safety awareness
✔ Pharmacist training & professional development
✔ Strengthening healthcare systems across states

This initiative reflects a shared commitment towards strengthening healthcare systems and advancing patient safety practices across the country.

hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag

Applications are invited for 37th Skill Development Programme on Pharmacovigilance scheduled from 15th-19th June 2026.
Registration Fee: INR 5,000/- (including GST)
Mode: Offline
Last Date of Application: 8th June 2026
Venue: NCC-PvPI, IPC, Ghaziabad, 201002
Registration link: https://docs.google.com/forms/d/e/1FAIpQLSegZ9V9TsR3S0HoQeU3oMf8jCdAShj1PIumouMqbireGJpaKw/viewform
Organized By: National Coordination Centre- Pharmacovigilance Programme of India, Indian Pharmacopoeia Commission.

Strengthening safety monitoring of leprosy medicines: Capacity Building Workshop for Pharmacovigilance and AMRfor DLOs of State Chhattisgarh

Pharmacovigilance ensures medicine safety and protects patients from harm. Its integration into public health programmes enhances patient safety, promotes rational use of medicines, prevents adverse drug reactions, and builds public trust in health systems. In 2025, WHO India, in collaboration with the Central Leprosy Division and the Pharmacovigilance Programme of India, rolled out pharmacovigilance in the National Leprosy Programme. In 2026, scale-up activities for pharmacovigilance of leprosy medicines are planned in Chhattisgarh and Maharashtra.
To support this initiative, the Central Leprosy Division, in collaboration with the Pharmacovigilance Programme of India–Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, and WHO India Country Office, organized a Capacity Building Workshop on Pharmacovigilance and Antimicrobial Resistance (AMR) for District Leprosy Officers of Chhattisgarh on 6 May 2026 at Raipur. The workshop brought together Medical Colleges, District Leprosy Officers, AMC coordinators, programme officials, and experts from WHO India and IPC.
The workshop focused on strengthening pharmacovigilance systems within the leprosy programme through sessions on ADR monitoring, reporting, causality assessment, operational linkages with ADR Monitoring Centres, and hands-on training on suspected ADR reporting forms for leprosy medicines.
The deliberations reinforced the need to strengthen ADR reporting systems for leprosy treatments and build the capacity of healthcare professionals for improved medicine safety monitoring and quality healthcare delivery in Chhattisgarh.

Registrations Now Open | Scientific Conclave & Interactive Session on Indian Pharmacopoeia 2026

“Significance of Indian Pharmacopoeia Reference Standards and Impurity Standards in Ensuring Pharmaceutical’s Quality”

Date: May 15, 2026 (Friday)
Time: 09:30 AM onwards
Venue: NIPER, Balanagar, Hyderabad, Telangana

This focused conclave will highlight:
• IP Monographs: Development & Revision Framework
• IPRS: Impurities & Reference Substances
• Elemental Impurities: Introduction & Overview and ICP-MS Estimation
• Control of Diethylene Glycol/Ethylene Glycol in Cough Syrups: Overview and update
• Nitrosamines: From Risk Assessment to Global Regulatory Actions
• Pharmacopoeia Impurities: Synthesis and Scope for Entrepreneurs
• Clinical relevance of impurity control in pharmaceuticals
• Interactive Discussion and Q&A

Who should attend:
• Pharmaceutical Manufacturers • Drug Testing Laboratories • Regulatory A airs Personnel • Analytical Scientists • Quality Control & Quality Assurance Professionals • Academia

Registration Fee: Rs. 1180/- (including 18% GST)

Seats are limited. Early registration is encouraged. Please register using the QR code provided in the event flyer, or you may register via this link: https://docs.google.com/forms/d/e/1FAIpQLSfgPIq4omFZcDbLG94jdokh7d7zni2uIceaqaqdnm13hbe9oA/viewform

The Indian Pharmacopoeia Commission, an autonomous institute of Ministry of Health and Family Welfare, Government of India invites quotations on Gem Portal (Government E marketplace) from eligible and qualified printing firms related to printing and binding of National Formulary of India (NFI-2026).

Click here to view the Bid Document:https://ipc.gov.in/images/library/GeM-Tender-Published.pdf

The Indian Pharmacopoeia Commission (IPC), Ghaziabad, successfully organized the “Scientific Conclave on Weights, pH and IP 2026 Updates”, in association with Mettler Toledo.

The seminar focused on the recent revisions to the Pharmacopoeial Standards and General Chapters on Weights & Balances and pH in the Indian Pharmacopoeia (IP) 2026, undertaken as part of ongoing harmonization efforts. The programme aimed to create awareness regarding these updates, explain their impact on laboratory operations and auditing processes, and guide participants on the necessary documentation required for compliance.
The session began with welcome and introductory remarks, setting the context for discussions on recent updates in the General Chapters of Indian Pharmacopoeia 2026. This was followed by detailed technical sessions focusing on revisions in balance and pH chapters, along with their implications for laboratory processes, including calibration procedures, measurement uncertainty, safety factors, and best practices before and after calibration.

Participants also engaged in practical demonstrations covering calibration certificates, 5-point calibration, system requirements for the pharmaceutical industry, and Good Electrochemistry Practice, providing hands-on technical insights. Discussions further addressed documentation requirements and the need for revising certain instruments within IPC chapters.

The conclave saw active participation from industry professionals, laboratory personnel, and regulatory stakeholders, serving as a platform for technical exchange and capacity building. The conclave reinforced IPC’s commitment to aligning IP standards with global benchmarks, strengthening quality assurance systems, and facilitating the wider acceptance of IP standards internationally.

Scientific Conclave on Indian Pharmacopoeia (IP) 2026 held at CSIR-IIIM, Jammu

The Indian Pharmacopoeia Commission (IPC), in collaboration with Council of Scientific and Industrial Research (CSIR), organized a Scientific Conclave and Interactive Session on Indian Pharmacopoeia (IP) 2026 at CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu.

The conclave brought together experts from regulatory bodies, academia, and the pharmaceutical sector to deliberate on key developments in pharmacopoeial standards and their role in ensuring the quality, safety, and efficacy of medicines.

The inaugural session featured addresses by senior officials and experts, highlighting the importance of strengthening drug standards in line with evolving scientific and regulatory requirements. The discussions emphasized the role of the Indian Pharmacopoeia as a critical tool in maintaining uniform standards for pharmaceuticals across the country.

The technical sessions focused on recent updates in Indian Pharmacopoeia (IP) 2026, including development and revision of monographs, strengthening of impurity standards, and adoption of modern analytical approaches.

Deliberations also covered regulatory perspectives, standardization of phytopharmaceuticals, and enhancement of microbiological and blood-related standards, reflecting a comprehensive approach towards improving pharmaceutical quality systems.

The interactive session provided a platform for stakeholders to exchange views on implementation aspects of IP 2026, industry preparedness, and the need for continued alignment with global standards. Participants highlighted the importance of collaboration between regulators, industry, and scientific institutions to ensure effective adoption of updated standards.

Registrations Now Open | Scientific Conclave and Interactive Session on Indian Pharmacopoeia (IP) 2026: An Ecosystem for Strengthening Quality Standards of Drugs/Pharmaceuticals
The Indian Pharmacopoeia Commission (IPC), in collaboration with CSIR-Indian Institute of Integrative Medicine (IIIM), invites registrations for the Scientific Conclave and Interactive Session on Indian Pharmacopoeia (IP) 2026.

Date: April 17, 2026 (Friday)
Time: 09:00 AM onwards
Venue: Auditorium, CSIR-IIIM, Jammu
This industry-focused conclave will highlight key scientific and regulatory developments under IP 2026.

Who should attend:
• Pharmaceutical manufacturers
• Quality Control and Quality Assurance professionals
• Regulatory affairs personnel
• Analytical scientists/academicians
• NGOs

Registration Fee: Rs. 1180/- (including 18% GST)
Seats are limited. Early registration is encouraged. Please register using the QR code provided in the event flyer.

The Indian Pharmacopoeia Commission (IPC) successfully commenced a two-day workshop on “Enhancing Scientific Publications in Pharmacopoeial Science and Pharmacovigilance” at IPC, Ghaziabad.

The keynote address was delivered by Padma Shri Prof. Balram Bhargava, eminent cardiologist, visionary scientist, and former Director General of the Indian Council of Medical Research and Secretary, Department of Health Research. Delivering the keynote address, Prof. Bhargava highlighted the importance of scientific integrity, impactful research, and responsible scientific communication in strengthening healthcare systems and advancing evidence-based public health.

In his address, Prof. Bhargava also reiterated the vision articulated by the Hon’ble Prime Minister Shri Narendra Modi — “Jai Jawan, Jai Kisan, Jai Vigyan, Jai Anusandhan” — underscoring the vital role of science and research in nation-building and in driving innovation for accessible and affordable healthcare.

During his visit, Prof. Bhargava also inaugurated the Reference Standard Division at the Advanced Level Research Centre of IPC, marking an important milestone in strengthening India’s capabilities in pharmacopoeial reference standards and quality assurance of medicines.

The workshop brings together experts, academicians, and researchers from leading institutions to deliberate on improving the quality, visibility, and global impact of scientific publications in pharmacopoeial science and pharmacovigilance.

IPC remains dedicated to fostering scientific excellence and strengthening India’s contribution to global pharmaceutical standards and public health research.